Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta ThalassemiaBusiness Wire • 01/27/23
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque PsoriasisBusiness Wire • 01/27/23
Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to DeclineZacks Investment Research • 01/26/23
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaBusiness Wire • 01/26/23
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 MillionBusiness Wire • 01/19/23
Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer DrugThe Motley Fool • 01/17/23
Bristol-Myers Squibb Co. (BMY) J.P. Morgan 41st Annual Healthcare Conference (Transcript)Seeking Alpha • 01/09/23
Bristol Myers Squibb to Present at J.P. Morgan's 41st Annual Healthcare ConferenceBusiness Wire • 01/03/23
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New YorkBusiness Wire • 01/03/23